Adrian Rawcliffe
2019
In 2019, Adrian Rawcliffe earned a total compensation of $2.1M as Chief Executive Officer at Adaptimmune Therapeutics, a 52% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $177,251 |
|---|---|
| Option Awards | $1,427,399 |
| Salary | $500,481 |
| Other | $43,125 |
| Total | $2,148,256 |
Rawcliffe received $1.4M in option awards, accounting for 66% of the total pay in 2019.
Rawcliffe also received $177.3K in non-equity incentive plan, $500.5K in salary and $43.1K in other compensation.
Rankings
In 2019, Adrian Rawcliffe's compensation ranked 5,557th out of 13,971 executives tracked by ExecPay. In other words, Rawcliffe earned more than 60.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,557 out of 13,971 | 60th |
Division Manufacturing | 2,081 out of 5,701 | 64th |
Major group Chemicals And Allied Products | 741 out of 2,200 | 66th |
Industry group Drugs | 622 out of 1,886 | 67th |
Industry Biological Products, Except Diagnostic Substances | 149 out of 389 | 62nd |
Source: SEC filing on April 20, 2020.
Rawcliffe's colleagues
We found four more compensation records of executives who worked with Adrian Rawcliffe at Adaptimmune Therapeutics in 2019.